Novo Nordisk v. Eli Lilly — Court Refuses to Block Comparative GLP-1 Ads
A New Jersey federal court denied Novo Nordisk a preliminary injunction against Eli Lilly’s comparative GLP-1 advertising because Novo failed to show irreparable harm and had used a similar advertising strategy itself.